← Leaderboards
Kevin Fitzgerald Gibson
University Of Pittsburgh At Pittsburgh
$513,749
Attributed
$1,027,498
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $817.7K · FY2012–14$1M$750K$500K$250K$0
'12
'13
'14
Funding mix
By agency
NIH$1,027,498 · 2
By mechanism
R01$732,010 · 1
U01$295,488 · 1
Top collaborators
- Steven R Duncan4 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Carol A Feghali-Bostwick$17,984,586
- Louis Justine Vuga$521,050
- Michael John Becich$31,335,131
- Joel S Greenberger$22,565,586
- Stephen R Wisniewski$41,152,197
Others in their field
Top investigators on “Outcome Forecast”
- Peter C Adamson · National Childhood Cancer Foundation$123,724,020
- Monica M Bertagnolli · Strang Cancer Prevention Center$50,120,149
- Norman Wolmark · Nsabp Foundation, Inc.$43,919,107
- Richard L Schilsky · University Of Chicago$40,064,700
- Walter John Curran · Thomas Jefferson University$35,876,624
- Ian M Thompson · University Of Texas Hlth Sci Ctr San Ant$27,122,576
Research focus
Outcome ForecastMonocyteSafetyDesignInflammatoryLungLung DiseasesPilot ProjectsClinical TrialsSteroidsAftercareAutoimmune ProcessAutoimmunityB Cell DifferentiationAutoimmune DiseasesAdrenal Cortex HormonesDisease ProgressionCritical IllnessChemokine (C-C Motif) Ligand 4Adverse EventAutoantibodiesClinical EfficacyCell MaturationB-Lymphocytes
Grant awards (4)
Rituximab Therapy in Patients with IPF$58,456
R01 · FY2014 · HL
Rituximab Therapy in Patients with IPF$673,554
R01 · FY2013 · HL
Impact of CCR5 inhibition on Sarcoid Immunophenotypes$144,111
U01 · FY2013 · HL · contact PI
Impact of CCR5 inhibition on Sarcoid Immunophenotypes$151,377
U01 · FY2012 · HL · contact PI